Jacob Eden M, Huang Jiaoti, Chen Ming
Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Precis Clin Med. 2024 Aug 1;7(3):pbae017. doi: 10.1093/pcmedi/pbae017. eCollection 2024 Sep.
The delivery of lipid nanoparticle (LNP)-based mRNA therapeutics has captured the attention of the vaccine research community as an innovative and versatile tool for treating a variety of human malignancies. mRNA vaccines are now in the limelight as an alternative to conventional vaccines owing to their high precision, low-cost, rapid manufacture, and superior safety profile. Multiple mRNA vaccine platforms have been developed to target several types of cancer, and many have demonstrated encouraging results in animal models and human trials. The effectiveness of these new mRNA vaccines depends on the efficacy and stability of the antigen(s) of interest generated and the reliability of their delivery to antigen-presenting cells (APCs), especially dendritic cells (DCs). In this review, we provide a detailed overview of mRNA vaccines and their delivery strategies and consider future directions and challenges in advancing and expanding this promising vaccine platform to widespread therapeutic use against cancer.
基于脂质纳米颗粒（LNP）的mRNA疗法作为一种创新且通用的治疗多种人类恶性肿瘤的工具，已引起疫苗研究界的关注。mRNA疫苗因其高精度、低成本、快速生产和卓越的安全性，作为传统疫苗的替代品而备受瞩目。已经开发了多种mRNA疫苗平台来靶向几种类型的癌症，并且许多在动物模型和人体试验中都显示出令人鼓舞的结果。这些新型mRNA疫苗的有效性取决于所产生的目标抗原的效力和稳定性，以及它们递送至抗原呈递细胞（APC），尤其是树突状细胞（DC）的可靠性。在这篇综述中，我们详细概述了mRNA疫苗及其递送策略，并探讨了将这一有前景的疫苗平台推进和扩展至广泛用于癌症治疗的未来方向和挑战。
